Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 14/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.39 |
| ▸ | MELK | Q14680 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3383971 | 0.81 | ROCK2 (0.46) | ROCK2ERN1ROCK1MELKPLAU | |
| SCHEMBL3384066 | 0.79 | ROCK2 (0.47) | ROCK2ERN1ROCK1 | |
| SCHEMBL3382086 | 0.76 | ROCK2 (0.54) | ROCK2ROCK1 | |
| SCHEMBL3387784 | 0.76 | ROCK2 (0.66) | ROCK2ROCK1 | |
| SCHEMBL3387411 | 0.76 | ROCK2 (0.53) | ROCK2ROCK1 | |
| SCHEMBL13362821 | 0.72 | PDE2A (0.33) | NTSR1PDE2A | |
| SCHEMBL13362766 | 0.71 | ROCK2 (0.44) | ROCK2ROCK1 | |
| SCHEMBL3389696 | 0.70 | ROCK2 (0.69) | ROCK2ROCK1 | |
| SCHEMBL13362729 | 0.70 | ROCK2 (0.42) | ROCK2ROCK1 | |
| SCHEMBL15818619 | 0.70 | NTSR1 (0.55) | NTSR1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010056758-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | FENG YANGBO (US) | 2010-05-20 | — | — | WO | disclosed |